Home Cart Sign in  
Chemical Structure| 1882-71-9 Chemical Structure| 1882-71-9

Structure of 1882-71-9

Chemical Structure| 1882-71-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1882-71-9 ]

CAS No. :1882-71-9
Formula : C8H10N2O2
M.W : 166.18
SMILES Code : O=C(N)C1=CC(OC)=CC=C1N
MDL No. :MFCD12674808
Boiling Point : No data available
InChI Key :NWZIAOBMRQYTTD-UHFFFAOYSA-N
Pubchem ID :20338217

Safety of [ 1882-71-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 1882-71-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 12
Num. arom. heavy atoms 6
Fraction Csp3 0.12
Num. rotatable bonds 2
Num. H-bond acceptors 2.0
Num. H-bond donors 2.0
Molar Refractivity 45.43
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

78.34 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.2
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.26
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.38
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.33
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.26
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.49

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.27
Solubility 8.88 mg/ml ; 0.0534 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.47
Solubility 5.68 mg/ml ; 0.0342 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.75
Solubility 2.97 mg/ml ; 0.0179 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

No
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-7.13 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.18

Application In Synthesis of [ 1882-71-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1882-71-9 ]
  • Downstream synthetic route of [ 1882-71-9 ]

[ 1882-71-9 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 1882-71-9 ]
  • [ 77287-34-4 ]
  • [ 19181-64-7 ]
YieldReaction ConditionsOperation in experiment
58% With ytterbium(III) triflate In 1,3,5-trimethyl-benzene at 165℃; for 6 h; Inert atmosphere General procedure: A mixture of 2-aminobenzamide (1, 4.0 mmol), carboxamide (2, 6.0 mmol), Yb(OTf)3 (0.20 mmol,5.0 molpercent), and mesitylene (5.0 mL) was placed in a 20-mL Pyrex flask equipped with a magnetic stirring bar and a reflux condenser under a flow of argon. The reaction was carried out at 120-165 oC (bath temp.) for 6 h with stirring. Then, the reaction mixture was cooled to room temperature, and analyzed by GLC, GC-MS (EI), and LC-MS (ESI). After evaporation of mesitylene under vacuum,the products (3) were isolated by recrystallization from MeOH/hexane and/or medium pressure column chromatography on silica gel (eluent: EtOAc/hexane = 50/50 ~ EtOAc 100percent. For 3j, eluent:MeOH/CHCl3 = 50/50). 1H NMR spectra were recorded at 400 MHz, and 13C NMR spectra wererecorded at 100 MHz in DMSO-d6. The analytical and spectral data of 3a-e,38 3f,39 3g,40 3h,41 and3j,42 were consistent with those reported previously. The product, 3i, was characterized below.
50% at 160℃; for 0.333333 h; Microwave irradiation Example30: (4-Chloro-phenyl)-{4-[(3S,4S)-4-hydroxy-l-(6-methoxy-quinazolin-4yl)- pyrrolidin-3-yl]-piperazin-l-yl}-methanone[00243] Step 1. 6-Methoxy-3H-quinazolin-4-one[00244] To 1.025 mmoles of 2-amino-5-methoxy anthranilic acid add 6.14 mmoles of formamide and microwave reaction mixture for 20mins at 1600C. After cooling the solid was diluted with 1OmL ethanol, the mixture was heated to reflux and allowed to cool slowly. The solid obtained was filtered and washed with cold ethanol and vaccum dried to give the title compound in 50percent yield.[00245] LC-MS: m/z = 177 (M+ +1)
References: [1] Heterocycles, 2015, vol. 90, # 2, p. 857 - 865.
[2] Patent: WO2006/71875, 2006, A1, . Location in patent: Page/Page column 91.
  • 2
  • [ 67-56-1 ]
  • [ 1882-71-9 ]
  • [ 19181-64-7 ]
YieldReaction ConditionsOperation in experiment
91% at 130℃; for 2 h; Inert atmosphere; Microwave irradiation 5-methoxybenzamide (83 mg, 0.5 mmol), [Cp * Ir (2,2'-bpyO) (H2O)](5.4 mg, 0.005 mmol, 1 molpercent), cesium carbonate (49 mg, 0.15 mmol, 0.3 equiv.) And methanolInto a dry 5mL microwave reaction tube. Nitrogen protection in microwave tube placed in a single mode pressure microwave synthesizerCEM, USA). After the reaction mixture was reacted at 130 ° C for 2 hours, it was cooled to room temperature. Solvent was removed by rotary evaporation and then passedColumn chromatography (developing solvent: petroleum ether / ethyl acetate) gave the pure target compound in a yield of 91percent
References: [1] Organic Letters, 2016, vol. 18, # 11, p. 2580 - 2583.
[2] Patent: CN107337646, 2017, A, . Location in patent: Paragraph 0045; 0046; 0047; 0048.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1882-71-9 ]

Aryls

Chemical Structure| 82049-00-1

A285034 [82049-00-1]

2-Amino-4-hydroxybenzamide

Similarity: 0.95

Chemical Structure| 63920-73-0

A436294 [63920-73-0]

2-Amino-4,6-dimethoxybenzamide

Similarity: 0.93

Chemical Structure| 960234-99-5

A105524 [960234-99-5]

3-Amino-5-methoxybenzamide

Similarity: 0.91

Chemical Structure| 3424-93-9

A122556 [3424-93-9]

4-Methoxybenzamide

Similarity: 0.85

Chemical Structure| 6705-03-9

A430658 [6705-03-9]

2-Amino-5-methoxybenzoic acid

Similarity: 0.82

Ethers

Chemical Structure| 63920-73-0

A436294 [63920-73-0]

2-Amino-4,6-dimethoxybenzamide

Similarity: 0.93

Chemical Structure| 960234-99-5

A105524 [960234-99-5]

3-Amino-5-methoxybenzamide

Similarity: 0.91

Chemical Structure| 3424-93-9

A122556 [3424-93-9]

4-Methoxybenzamide

Similarity: 0.85

Chemical Structure| 6705-03-9

A430658 [6705-03-9]

2-Amino-5-methoxybenzoic acid

Similarity: 0.82

Chemical Structure| 2439-77-2

A622691 [2439-77-2]

2-Methoxybenzamide

Similarity: 0.80

Amides

Chemical Structure| 82049-00-1

A285034 [82049-00-1]

2-Amino-4-hydroxybenzamide

Similarity: 0.95

Chemical Structure| 63920-73-0

A436294 [63920-73-0]

2-Amino-4,6-dimethoxybenzamide

Similarity: 0.93

Chemical Structure| 960234-99-5

A105524 [960234-99-5]

3-Amino-5-methoxybenzamide

Similarity: 0.91

Chemical Structure| 3424-93-9

A122556 [3424-93-9]

4-Methoxybenzamide

Similarity: 0.85

Chemical Structure| 146224-62-6

A312457 [146224-62-6]

4-Amino-3-hydroxybenzamide

Similarity: 0.81

Amines

Chemical Structure| 82049-00-1

A285034 [82049-00-1]

2-Amino-4-hydroxybenzamide

Similarity: 0.95

Chemical Structure| 63920-73-0

A436294 [63920-73-0]

2-Amino-4,6-dimethoxybenzamide

Similarity: 0.93

Chemical Structure| 960234-99-5

A105524 [960234-99-5]

3-Amino-5-methoxybenzamide

Similarity: 0.91

Chemical Structure| 3424-93-9

A122556 [3424-93-9]

4-Methoxybenzamide

Similarity: 0.85

Chemical Structure| 6705-03-9

A430658 [6705-03-9]

2-Amino-5-methoxybenzoic acid

Similarity: 0.82